A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:
Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.
The primary outcome is the euploidy rate of blastocysts.

开始日期2024-12-01

申办/合作机构

上海集爱遗传与不育诊疗中心

NCT06175832 / Not yet recruiting临床4期IIT

PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study

P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.

开始日期2024-11-01

申办/合作机构

Ghent University Hospital

NCT06637189 / Not yet recruiting临床4期IIT

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients.
The aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.

开始日期2024-10-15

申办/合作机构

Theramex HQ UK Ltd.初创企业

100 项与卵巢刺激相关的临床结果

登录后查看更多信息

100 项与卵巢刺激相关的转化医学

登录后查看更多信息

0 项与卵巢刺激相关的专利（医药）

登录后查看更多信息

191

项与卵巢刺激相关的文献（医药）

2024-10-01·Cancer Reports

Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors

Article

作者: Farazestanian, Marjaneh ; Yousefi, Zohreh ; Homaei Shandiz, Fatemeh ; Mottaghi, Mansoureh ; Golmohammadi Tavallaee, Mansoureh ; Hasanzadeh Mofrad, Malihe ; Hamidi, Bahram ; Davachi, Behrouz ; Afzaljavan, Fahimeh

ABSTRACTPurposeGranulosa cell tumors (GCTs) of the ovary are rare but clinically significant malignancies. Despite advances in treatment, recurrence has remained a substantial challenge. This study aimed to identify clinical outcomes and potential prognostic risk factors for recurrence in patients diagnosed with GCTs.MethodsIn a retrospective cohort study, the ovarian cancer database of the gynecological tertiary referral cancer center, Mashhad University of Medical Sciences, Mashhad, Iran, was searched from August 2012 to August 2023 to find GCT cases. Demographic, clinical, pathological, intervention‐related factors, follow‐up, and survival findings were meticulously collected. Data were analyzed using SPSS v 23.ResultsNinety‐two patients with GCTs, including 86 AGCT and 6 JGCT subjects, were identified. Based on further analysis of AGCT patients, most patients were ages under 50 (58.1%), clinically presented pain (32.6%), and abnormal uterine bleeding (27.9%) as the most frequent symptoms. Stages IA (64.0%) and IC (20.9%) were common. Five‐year overall and progression‐free survival were 98.2% and 90.8%, respectively. With a median follow‐up time of 72 (0.0–180) months, disease recurrence was observed in 19 patients (23.9%), and five patients (5.4%) died of the disease. Stage IV was a hazard factor of recurrence (HR = 7.62, 95%CI (1.89–30.63); p = 0.004).ConclusionsThe present study provides valuable insights into the outcomes and potential risk factors for recurrence in ovarian AGCTs. It duplicates the importance of stage in the prognosis of AGCT patients and highlights the safety of fertility‐sparing surgery in stage I and the lack of need to administer chemotherapy in stage IC.

2024-10-01·Pathology

Intraoperative frozen section evaluation of ovarian sex cord-stromal tumours and their mimics: a study of 121 cases with emphasis on potential diagnostic pitfalls

Article

作者: Li, Junsiyuan ; Wong, Shing Lih ; Chua, Hui Min ; Cheng, Chee Leong ; Chng, Jason Kiat Soon ; Lim, Gek Hsiang ; Tan, Puay Hoon ; Zhao, Zitong ; Zeng, Lixia ; Shi, Ruoyu ; Ang, Joella Xiaohong ; Ngo, Nye Thane

Ovarian sex cord-stromal tumours (SCSTs) present diagnostic difficulties during frozen section (FS) consultations due to their diverse morphology. This study aimed to evaluate the accuracy of FS evaluation of SCSTs in our institution, as well as to examine the reasons leading to incorrect FS diagnosis. Cases mimicking SCSTs and diagnosed as such during FS were also highlighted. We analysed 121 ovarian SCST cases and their mimics which underwent FS consultations over a 10-year period, to evaluate FS accuracy, reasons for deferrals and discrepancies. FS diagnoses were concordant, deferred and discrepant compared to the final diagnosis in 50 (41.3%), 39 (32.2%) and 32 (26.5%) cases, respectively. Major discrepancies (9/121, 7.4%) were mostly related to the diagnosis of adult granulosa cell tumour (AGCT). A fibromatous AGCT was misinterpreted as fibroma on FS, while a cystic AGCT was called a benign cyst. Conversely, a mesonephric-like adenocarcinoma, a sertoliform endometrioid carcinoma and a thecoma were misinterpreted as AGCT on FS. Another discrepant case was a Krukenberg tumour with prominent fibromatous stroma in which malignant signet ring cells were overlooked and misinterpreted as fibroma. Minor discrepancies were primarily associated with fibroma (21/23, 91.3%), wherein minor but potentially impactful details such as cellular fibroma and mitotically active cellular fibroma were missed due to sampling issues and misinterpretation as leiomyoma. FS evaluation for ovarian SCSTs demonstrated an overall accuracy of 78.5%, 81.0% and 81.8% for benign, uncertain/low malignant potential and malignant categories, respectively. There was no FS-related adverse clinical impact in all cases with available follow-up information (120/121 cases). Intraoperative FS evaluation of ovarian SCSTs is challenging. A small number of cases were misinterpreted, with AGCTs being the primary group where errors occur. Awareness of common diagnostic pitfalls and difficulties, alongside application of a stepwise approach, including (1) obtaining comprehensive clinical information, (2) thorough macroscopic examination and directed sampling, (3) meticulous microscopic examination with consideration of pitfalls and mimics, (4) effective communication with surgeons in difficult cases, and (5) consultation of subspecialty colleagues in challenging cases, will enhance pathologists' reporting accuracy and management of such cases in the future.

2024-10-01·Journal of Zhejiang University (Medical Sciences)

The best evidence for the management of ovarian hyper-stimulation syndrome in patients undergoing assisted reproductive therapy

Article

作者: He, Yu ; Shen, Xuling ; Jiang, Xuechun ; Xu, Meiling ; Wei, Qun ; Zhang, Yongmei ; Wang, Zilian

目的: 总结辅助生殖技术治疗患者卵巢过度刺激综合征管理的最佳证据，为医护人员管理卵巢过度刺激综合征提供循证依据。方法: 系统检索UpToDate、BMJ Best Practice、世界卫生组织（WHO）网站、国际指南协作网（GIN）、英国国家医疗保健优化研究所（NICE）网站、美国国立指南网、美国生殖医学会（ASRM）网站、纽约科学院（NYAS）网站、澳大利亚乔安娜布里格斯研究所（JBI）循证卫生保健中心数据库、Cochrane Library、CINAHL、PubMed、万方数据、中国知网和中国生物医学文献数据库中与辅助生殖技术治疗患者卵巢过度刺激综合征管理有关的证据，包括指南、临床决策、最佳临床实践、系统评价、专家共识、证据总结及相关原始研究。检索时限为建库至2024年5月31日。两名受过循证护理培训的研究人员独立进行文献质量评价，出现分歧时由第三名循证护理专家进行判断，最终决定纳入或剔除文献。结果: 共纳入15篇文献，经质量评价后剔除1篇，剩余14篇包括5篇指南、3篇系统评价、2篇专家共识、1篇证据总结和UpToDate中的3篇。最终得到包括风险评估、病情监测、早期预防、制度管理、健康教育五个方面共27条最佳证据。结论: 医护人员应早期开展卵巢过度刺激综合征的监测和预防，为患者提供个性化治疗方案，促使治疗资源得到合理配置，以提升对卵巢过度刺激综合征患者的有效管理。.

项与卵巢刺激相关的新闻（医药）

2024-10-18

·BioSpace

Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress

Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually. “We are pleased to share new data at this year’s ASRM Congress that provides healthcare professionals and fertility clinic staff with important research, findings and insights that they can apply in their clinical practice,” said Sasmira Lalwani, Senior Medical Director, Reproductive Medicine, Ferring Pharmaceuticals. “Our data presentations underscore our goal of advancing the science, supporting diverse family-building needs and providing educational resources for healthcare professionals because we understand there’s not a ‘one-size-fits-all’ approach to fertility care.” The four abstracts being presented by Ferring cover a wide range of timely and critical topics in reproductive medicine. Abstract Title Presentation Details - All times MDT Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions Poster #24 EMBARGOED UNTIL: October 21 10:45 – 11:00 a.m. Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey Oral Presentation #184 EMBARGOED UNTIL: October 22 11:45 – 11:56 a.m. Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis Oral Presentation #154 EMBARGOED UNTIL: October 22 10:56 – 11:07 a.m. Assessing the Impact of an eLearning Platform for Educating Fertility Professionals Poster #652 EMBARGOED UNTIL: October 23 11:30 – 11:45 a.m. “For more than 50 years, Ferring has been relentless in our pursuit to help more people become parents by working to address the evolving needs within reproductive medicine,” said David Powley, Vice President, Reproductive Medicine and Operations, Ferring Pharmaceuticals. “ASRM is an important opportunity to share more about our contributions and long-standing investment in areas such as our product portfolio and pipeline, focus on expanding access to in vitro fertilization and work with healthcare professionals to help improve the patient experience and outcomes.” Along with the four data presentations, Ferring will also host an informative discussion entitled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” (October 21st at 10:05 a.m. MDT). The moderated panel discussion highlights the state and federal legislative, policy and health equity advances to expand access to family building care and infertility treatment. Moderator : Tim Clark, Director of Government Affairs, Ferring Panelists : Serena H. Chen, MD, Reproductive Endocrinologist, Division Director Emeritus & Director of Advocacy, CCRM NJ - IRMS Reproductive Medicine Michael A. Thomas, MD, Professor and Chair, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine and Immediate Past President, American Society for Reproductive Medicine Sean B. Tipton, MA, Chief Advocacy & Policy Officer, American Society for Reproductive Medicine About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit , call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn , and X (Twitter) . Contacts For more information, please contact: Lisa Perdomo Director, Brand Communications Ferring Pharmaceuticals +1-862-341-9820 lisa.perdomo@ferring.com